Cagrilintide/semaglutide
RASMUS
Novo Nordisk · Phase 1 · Recruiting · Enrollment 100
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| CagriSema | Obesity or overweight | n/r | 52 | n/r | n/r |
| Semaglutide | Obesity or overweight | n/r | 52 | n/r | n/r |
| Cagrilintide | Obesity or overweight | n/r | 52 | n/r | n/r |
| Placebo | Obesity or overweight | n/r | 52 | n/r | n/r |